Beta-lactamase inhibitors

1. A compound of Formula (I) or Formula (II) or pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, or N-oxides thereof:

wherein:

L is —(CR 2 R 3 )—;

n is 0, 1, 2, 3, 4, 5, or 6;

p is 1 or 2;

X 1 and X 2 are independently selected from —OH, —OR x , and F;

AzA is a five-membered heteroaromatic ring system bearing at least three N heteroatoms;

Y is selected from the group consisting of fluoro, chloro, bromo, iodo, optionally substituted C 1 -C 6 alkyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted aryl, optionally substituted heteroaryl, and —(CR 9 R 10 ) v NR 6 R 7 , wherein at least one Y is —(CR 9 R 10 ) v NR 6 R 7

v is 1-4;

R a , R b , and R c are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, —OH, —OR 11 , —NR 6 R 7 , and —SR 11 ;

R e is hydrogen, optionally substituted C 1 -C 6 alkyl, or optionally substituted C 3 -C 6 cycloalkyl;

each R x is independently optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted alkoxyalkyl, optionally substituted hydroxyalkyl, optionally substituted aminoalkyl, optionally substituted heterocycle, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclealkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, (poly ethylene glycol) ethyl, or an optionally substituted saccharide;

or two R x taken together with the atoms to which they are attached form an optionally substituted heterocycle;

R 1 is hydrogen, R 31 , —(R 30 ) q OR 31 , —(R 30 ) q O(R 30 ) q OR 31 , —R 30 OC(O)R 31 , —R 30 OC(O)OR 31 , —R 30 OC(O)NHR 31 , —R 30 OC(O)N(R 31 ) 2 , optionally substituted alkyloxyalkyl, optionally substituted acyloxyalkyl, optionally substituted alkyloxycarbonyloxyalkyl, optionally substituted cycloalkyloxycarbonyloxyalkyl, optionally substituted aryloxycarbonyloxyalkyl, or optionally substituted alkyl-[1,3]dioxol-2-one;

each q is independently 2, 3, 4, 5, or 6;

each R 30 is independently —CH 2 —, —CH(CH 3 )—, —C(CH 3 ) 2 —, or optionally substituted 1,1′-cyclopropylene;

each R 31 is optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, C 3 -C 8 cycloalkyl, C 3 -C 8 heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylcycloalkyl, optionally substituted alkylheterocyclyl, optionally substituted alkylaryl, or optionally substituted alkylheteroaryl; or

two R 31 are taken together with the nitrogen to which they are attached to form a C 3 -C 8 heterocyclyl;

each R 2 and R 3 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, —OH, —OR 11 , —SR 11 , —NR 6 R 7 , —(CR 9 R 10 ) v C(O)NR 6 R 7 , —(CR 9 R 10 ) v C(O)OH, —(CR 9 R 10 ) v OH, —(CR 9 R 10 ) v NR 6 R 7 , and —(CR 9 R 10 ) v N(R 6 )C(═NR 8 )NR 6 R 7 ;

or R 2 and R 3 on the same carbon are taken together to form an oxo or optionally substituted oxime;

or R 2 and R 3 on the same carbon are taken together to form an optionally substituted spiro-carbocycle or optionally substituted spiro-heterocycle with the carbon to which they are attached;

or when n is at least 2, two R 2 on different carbons are taken together form an optionally substituted carbocycle or optionally substituted heterocycle with the carbons to which they are attached;

or when n is at least 2, two R 2 on adjacent carbons are taken together to form a double bond; or two R 2 and two R 3 on adjacent carbons are taken together to form a triple bond;

each R d , R 6 and R 7 are independently selected from the group consisting of hydrogen, —CN, —OH, —S(O) 2 R 11 , —S(O) 2 NH 2 , optionally substituted C 1 -C 6 alkyl, optionally substituted alkoxyalkyl, optionally substituted hydroxyalkyl, optionally substituted aminoalkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted aralkyl, optionally substituted heteroaralkyl, (poly-ethylene-glycol)-ethyl, and an optionally substituted saccharide;

or R 6 and R 7 taken together form an optionally substituted heterocycle with the nitrogen to which they are attached;

each R 8 is independently hydrogen, —OH, —OR 11 , —CN, —NO 2 , —NR 6 , or optionally substituted C 1 -C 6 alkyl;

each R 9 and R 10 are independently selected from the group consisting of hydrogen, fluoro, chloro, bromo, optionally substituted C 1 -C 6 alkyl, optionally substituted alkoxyalkyl, optionally substituted hydroxyalkyl, optionally substituted C 3 -C 6 cycloalkyl, —OH, —OR 11 , —SR 11 , —NR 6 R 7 , —NR 6 C(O)R 11 , —(CR a R b ) v NR 6 R 7 , —(CR a R b ) v C(O)NR 6 R 7 , —C(O)NR 6 R 7 , —C(O)OR 11 , —C(O)OH, —NR 6 SO 2 R 11 , optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl;

or R 9 and R 10 taken together with the carbon atom to which they are attached form an optionally substituted oxime, an optionally substituted carbocycle, or an optionally substituted heterocycle; and

each R 11 is independently optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 6 cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted aryl.

2. The compound of claim 1 , wherein R a , R b , and R c are independently selected from the group consisting of hydrogen, fluoro, chloro, —OH, and —OCH 3 .

3. The compound of claim 1 , wherein X 1 is —OH and X 2 is —OH when present.

4. The compound of claim 1 , wherein R d is hydrogen.

5. The compound of claim 1 , wherein n is 1, 2, or 3.

6. The compound of claim 1 , wherein each R 2 and R 3 are hydrogen.

7. The compound of claim 1 , wherein R 1 is hydrogen, R 31 , —R 30 OC(O)R 31 , or —R 30 OC(O)OR 31 ; each R 30 is independently —CH 2 —, —CH(CH 3 )—, or —C(CH 3 ) 2 —; and each R 31 is optionally substituted C 1 -C 12 alkyl, optionally substituted C 2 -C 12 alkenyl, optionally substituted C 2 -C 12 alkynyl, C 3 -C 8 cycloalkyl, C 3 -C 8 heterocyclyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylcycloalkyl, optionally substituted alkylheterocyclyl, optionally substituted alkylaryl, or optionally substituted alkylheteroaryl.

8. The compound of claim 1 , wherein R 1 is hydrogen.

9. The compound of claim 1 , wherein (Y) p -AzA is selected from:

10. The compound of claim 1 , wherein (Y) p -AzA is selected from:

11. The compound of claim 1 , wherein p is 1 or 2.

12. The compound of claim 1 , wherein each R 6 and R 7 are independently selected from the group consisting of hydrogen and optionally substituted C 1 -C 6 alkyl.

13. The compound of claim 1 , wherein R 9 and R 10 are hydrogen and v is 1 or 2.

14. The compound of claim 1 that is selected from the group consisting of:

or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, or N-oxide thereof.

15. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt, solvate, stereoisomer, tautomer, or N-oxide thereof, and a pharmaceutically acceptable excipient.

16. The pharmaceutical composition of claim 15 , further comprising a beta-lactam antibiotic.

17. A method of treating a bacterial infection in a subject, comprising administering to the subject a compound of claim 1 , optionally in combination with a beta-lactam antibiotic.